Compare Kyndryl Holdings Inc (KD) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kyndryl Holdings Inc vs Twist Bioscience Corp — how do they compare? Kyndryl Holdings Inc trades at $11.75 (market cap $2.59B), while Twist Bioscience Corp trades at $159.78 (market cap $10.08B). The key difference: Twist Bioscience Corp is far larger — about 3.9× Kyndryl Holdings Inc's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Kyndryl Holdings Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Kyndryl Holdings Inc for 36 Days and Twist Bioscience Corp for 27 Days on average.
| KD | TWST | |
|---|---|---|
Market Cap | $2.59B | $10.08B |
Volume | 5,354,348 | 4,229,037 |
Sector | Technology | Health |
52-Week High | $28.92 | $205.00 |
52-Week Low | $10.59 | $25.45 |
Typical Hold Time | 36 Days | 27 Days |
Enterprise Value | $5.41B | $10.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kyndryl Holdings (KD) trades at $11.88, up 3.76% today, showing recent volatility amid mixed technical signals. The company reported positive net income of $252 million in 2025, marking a significant turnaround from prior losses, though revenue has declined from $18.3B in 2022 to $15.1B. Recent news highlights Kyndryl's strategic focus on AI, including the launch of an innovation lab and acquisition of Healthcare IT Leaders to drive growth.
Outlook remains cautious with analyst consensus leaning Hold (71% of ratings) and a $14.67 price target suggesting moderate upside. Key risks include declining revenue trends and competitive pressures in IT services, while opportunities lie in AI-driven modernization contracts and improved profitability. Investors should weigh the turnaround progress against execution risks in a challenging market.
TWST trades at $152.05, down 2.31% today, with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported Q2 2026 EPS of -$0.56, missing expectations, continuing a trend of losses despite revenue growth to $376.57M in 2025. Recent news highlights a partnership with Lilly TuneLab for AI-driven drug discovery, driving investor optimism.
Outlook remains speculative with high valuation multiples (P/S 21.5, P/B 22.62) and persistent losses, but analyst consensus is bullish (73% buy ratings) with a $145.20 price target. Key risks include cash burn, competitive pressures, and reliance on AI-driven growth catalysts for profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kyndryl Holdings Inc
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.
Read more on KD →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
